1256639-86-7
Chemical Structure
Daunorubicin-Cytarabine Liposome
Synonym(s): CPX 351; Cytarabine-daunorubicin
- CAS No.: 1256639-86-7
- Formula:C36H42N4O15
- Molecular Weight:770.74
InChIKey: HBQCEICSYDCGJG-SZXLQUARSA-N
SMILES: OC1=C(C(C2=CC=CC(OC)=C2C3=O)=O)C3=C(O)C4=C1C[C@](C(C)=O)(O)C[C@@H]4O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)N.O[C@H]6[C@H](O)[C@H](N7C(N=C(C=C7)N)=O)O[C@@H]6CO
Biological Activity: Cytarabine-daunorubicin (CPX 351) is a Liposomal formulation prepared from Cytarabine (HY-13605) and Daunorubicin (HY-13062A) at a fixed synergistic molar ratio of 5:1. Cytarabine-daunorubicin improves secondary acute myeloid leukemia. Cytarabine-daunorubicin can be used in research related to secondary acute myeloid leukemia, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Daunorubicin-Cytarabine Liposome | Cytarabine-daunorubicin (CPX 351) is a Liposomal formulation prepared from Cytarabine (HY-13605) and Daunorubicin (HY-13062A) at a fixed synergistic molar ratio of 5:1. Cytarabine-daunorubicin improves secondary acute myeloid leukemia. Cytarabine-daunorubicin can be used in research related to secondary acute myeloid leukemia, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Lancet JE, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018;36(26):2684-2692. [Content Brief]
- [2]. Peterlin P, et al. CPX 351 as first line treatment in higher risk MDS. A phase II trial by the GFM[J]. Blood, 2021, 138: 243.
Keywords
